Compass Therapeutics (CMPX) Cash & Equivalents (2018 - 2026)
Compass Therapeutics (CMPX) posted Cash & Equivalents of $55.2 million for Q1 2026, up 76.76% sequentially from $31.2 million in Q4 2025, and up 34.4% YoY from $41.0 million in Q1 2025.
Compass Therapeutics (CMPX) Cash & Equivalents (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $55.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 34.4% year-over-year to $55.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.2 million (up 34.4% YoY) and the FY2025 annual result came in at $31.2 million, down 29.15% from the prior year.
- Cash & Equivalents grew to $55.2 million in Q1 2026 per CMPX's latest filing, from $31.2 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $136.4 million in Q1 2022 and troughed at $16.5 million in Q3 2022.
- A 5-year average of $36.4 million and a median of $27.0 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 243.57% in 2022, then sank 80.18% in 2023.
- Over 5 years, Cash & Equivalents stood at $34.9 million in 2022, then sank by 30.58% to $24.2 million in 2023, then surged by 81.82% to $44.1 million in 2024, then dropped by 29.15% to $31.2 million in 2025, then jumped by 76.76% to $55.2 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $55.2 million, $31.2 million, and $46.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | 36.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.02 Mn |
| Mar 31, 2026 | 55.17 Mn |
| Dec 31, 2025 | 31.21 Mn |
| Sep 30, 2025 | 46.21 Mn |
| Jun 30, 2025 | 22.86 Mn |
| Mar 31, 2025 | 41.05 Mn |
| Dec 31, 2024 | 44.05 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Jun 30, 2024 | 19.40 Mn |
| Mar 31, 2024 | 23.99 Mn |
| Dec 31, 2023 | 24.23 Mn |
| Sep 30, 2023 | 30.43 Mn |
| Jun 30, 2023 | 19.28 Mn |
| Mar 31, 2023 | 27.03 Mn |
| Dec 31, 2022 | 34.90 Mn |
| Sep 30, 2022 | 16.48 Mn |
| Jun 30, 2022 | 26.24 Mn |
| Mar 31, 2022 | 136.38 Mn |
| Dec 31, 2021 | 144.51 Mn |
| Sep 30, 2021 | 25.51 Mn |